Serac’s imaging agent marks a breakthrough in endometriosis detection
Early-stage endometriosis now visible through non-invasive imaging
Read More
Tag: data
AMO Pharma reveals data from myotonic dystrophy study
Clinically significant results have emerged from trial evaluating the company’s AMO-02 candidate
Read More
Novartis reveals vital Leqvio data
The therapy involves treating individuals with atherosclerotic cardiovascular disease
Read More
Positive data for Caribou Biosciences’ CB-010 candidate
CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma
Read More
Calliditas reveals pivotal setanaxib data
Results are from company’s phase 2 head and neck cancer trial with lead NOX inhibitor candidate
Read More
Janssen reveals new Spravato data
Period to remission was shortened with esketamine nasal spray in both sub-groups within study
Read More
Novartis reveals five-year efficacy data for Kesimpta
Patients treated with Kesimpta experienced considerable decreases in relapse rates
Read More
Positive efficacy data for Sensorian’s candidate
SENS-401 has been developed for hearing preservation among adult patients following cochlear implantation
Read More
Teva reveals critical Ajovy data
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
Read More
University of Oxford and PrecisionLife reach data agreement
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis
Read More
TME Pharma reveals positive NOX-A12 data
GLORIA trial shows increased survival levels among newly diagnosed brain cancer patients
Read More
Positive results for Astellas’ Fezolinetant
Trial involved over 450 women across Europe, Turkey and Canada who were unsuitable for hormone therapy
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
